Probing chemical space with alkaloid-inspired libraries

Nature Chemistry

Volumn 6, Issue 2, 2014, Pages 133-140

  McLeod, Michael C ^a   Singh, Gurpreet ^a   Plampin, James N ^a   Rane, Digamber ^a   Wang, Jenna L ^a   Day, Victor W ^a   Aubé, Jeffrey ^a  

^a UNIVERSITY OF KANSAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALOID; AMARYLLIDACEAE ALKALOID; BIOLOGICAL PRODUCT; LEPADIFORMINE;

ARTICLE; CHEMISTRY; CYCLOADDITION; MOLECULAR LIBRARY; SYNTHESIS;

ALKALOIDS; AMARYLLIDACEAE ALKALOIDS; BIOLOGICAL PRODUCTS; CYCLOADDITION REACTION; SMALL MOLECULE LIBRARIES;

EID: 84893020694     PISSN: 17554330     EISSN: 17554349     Source Type: Journal    
DOI: 10.1038/nchem.1844     Document Type: Article

References (48)

1. Newman, D. J. & Cragg, G. M. Natural products as sources of new drugs over the last 25 years. J. Nat. Prod. 70, 461-477 (2007). (Pubitemid 46595760)
2. Butler, M. S. Natural products to drugs: natural product-derived compounds in clinical trials. Nat. Prod. Rep. 25, 475-516 (2008). (Pubitemid 351725315)
3. Paterson, I. & Anderson, E. A. Chemistry. The renaissance of natural products as drug candidates. Science 310, 451-453 (2005). (Pubitemid 41507948)
4. Ganesan, A. The impact of natural products upon modern drug discovery. Curr. Opin. Chem. Biol. 12, 306-317 (2008).
5. Lipinski, C. A., Lombardo, F., Dominy, B. W. & Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 23, 3-25 (1997). (Pubitemid 27046991)
6. Boldi, A. M. Libraries from natural product-like scaffolds. Curr. Opin. Chem. Biol. 8, 281-286 (2004). (Pubitemid 38759403)
7. Thomas, G. L. & Johannes, C. W. Natural product-like synthetic libraries. Curr. Opin. Chem. Biol. 15, 516-522 (2011).
8. Camp, D., Davis, R. A., Evans-Illidge, E. A. & Quinn, R. J. Guiding principles for natural product drug discovery. Future Med. Chem. 4, 1067-1084 (2012).
9. Lachance, H., Wetzel, S., Kumar, K. & Waldmann, H. Charting, navigating, and populating natural product chemical space for drug discovery. J. Med. Chem. 55, 5989-6001 (2012).
10. Zuegg, J. & Cooper, M. A. Drug-likeness and increased hydrophobicity of commercially available compound libraries for drug screening. Curr. Top. Med. Chem. 12, 1500-1513 (2012).
11. Njardarson, J. T., Gaul, C., Shan, D., Huang, X-Y. & Danishefsky, S. J. Discovery of potent cell migration inhibitors through total synthesis: lessons from structure-activity studies of (and)-migrastatin. J. Am. Chem. Soc. 126, 1038-1040 (2004). (Pubitemid 38140731)
12. Szpilman, A. M. & Carreira, E. M. Probing the biology of natural products. Molecular editing by diverted total synthesis. Angew. Chem. Int. Ed. 49, 9592-9628 (2010).
13. Wetzel, S., Bon, R. S., Kumar, K. & Waldmann, H. Biology-oriented synthesis. Angew. Chem. Int. Ed. 50, 10800-10826 (2011).
14. Burke, M. D. & Schreiber, S. L. A planning strategy for diversity-oriented synthesis. Angew. Chem. Int. Ed. 43, 46-58 (2004). (Pubitemid 38063470)
15. Huigens, R. W. et al. A ring-distortion strategy to construct stereochemically complex and structurally diverse compounds from natural products. Nature Chem. 5, 195-202 (2013).
16. Kim, Y. K. et al. Relationship of stereochemical and skeletal diversity of small molecules to cellular measurement space. J. Am. Chem. Soc. 126, 14740-14745 (2004).
17. Shelat, A. A. & Guy, R. K. Scaffold composition and biological relevance of screening libraries. Nature Chem. Biol. 3, 442-446 (2007). (Pubitemid 47080378)
18. Lovering, F., Bikker, J. & Humblet, C. Escape from flatland: increasing saturation as an approach to improving clinical success. J. Med. Chem. 52, 6752-6756 (2009).
19. Clemons, P. A. et al. Quantifying structure and performance diversity for sets of small molecules comprising small-molecule screening collections. Proc. Natl Acad. Sci. USA 108, 6817-6822 (2011).
20. Lovering, F. Escape from flatland 2: complexity and promiscuity. MedChemComm 4, 515-519 (2013).
21. Nandy, J. P. et al. Advances in solution- and solid-phase synthesis toward the generation of natural product-like libraries. Chem. Rev. 109, 1999-2060 (2009).
22. MacLellan, P. & Nelson, A. A conceptual framework for analysing and planning synthetic approaches to diverse lead-like scaffolds. Chem. Commun. 49, 2383-2393 (2013).
23. Evans, B. E. et al. Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists. J. Med. Chem. 31, 2235-2246 (1988). (Pubitemid 19001640)
24. DeSimone, R. W., Currie, K. S., Mitchell, S. A., Darrow, J. W. & Pippin, D. A. Privileged structures: applications in drug discovery. Comb. Chem. High T. Scr. 7, 473-493 (2004). (Pubitemid 39108267)
25. Costantino, L. & Barlocco, D. Privileged structures as leads in medicinal chemistry. Curr. Med. Chem. 13, 65-85 (2006).
26. Duarte, C. D., Barreiro, E. J. & Fraga, C. A. M. Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini-Rev. Med. Chem. 7, 1108-1119 (2007). (Pubitemid 350200217)
27. Costantino, L. & Barlocco, D. Privileged structures as leads in medicinal chemistry. Front. Med. Chem. 5, 381-422 (2010).
28. Verma, A. et al. Nitrogen-containing privileged structures and their solid phase combinatorial synthesis. Comb. Chem. High T. Scr. 16, 345-393 (2013).
29. Frankowski, K. J. et al. Synthesis and receptor profiling of Stemona alkaloid analogues reveal a potent class of sigma ligands. Proc. Natl Acad. Sci. USA 108, 6727-6732 (2011).
30. Pilli, R. A., Rosso, G. B. & de Oliveira, M. d. C. F. The Stemona alkaloids. Alkaloids 62, 77-173 (2005). (Pubitemid 43589096)
31. Pilli, R. A., Rosso, G. B. & de Oliveira, M. d. C. F. The chemistry of Stemona alkaloids: an update. Nat. Prod. Rep. 27, 1908-1937 (2010).
32. Weinreb, S. M. Studies on total synthesis of the cylindricine/ fasicularin/ lepadiformine family of tricyclic marine alkaloids. Chem. Rev. 106, 2531-2549 (2006).
33. Gericke, N. & Viljoen, A. M. Sceletium - a review update. J. Ethnopharm. 119, 653-663 (2008).
34. Perez, E. G., Mendez-Galvez, C. & Cassels, B. K. Cytisine: a natural product lead for the development of drugs acting at nicotinic acetylcholine receptors. Nat. Prod. Rep. 29, 555-567 (2012).
35. Daly, J.W. Nicotinic agonists, antagonists, and modulators from natural sources. Cell. Mol. Neurobiol. 25, 513-552 (2005). (Pubitemid 41199710)
36. Wrobleski, A., Coombs, T. C., Huh, C. W., Li, S-W. & Aubé, J. The Schmidt reaction. Org. React. 78, 1-320 (2012).
37. Zeng, Y., Reddy, D. S., Hirt, E. & Aube, J. Domino reactions that combine an azido-Schmidt ring expansion with the Diels-Alder reaction. Org. Lett. 6, 4993-4995 (2004). (Pubitemid 40125860)
38. Gracias, V., Frank, K. E., Milligan, G. L. & Aubé, J. Ring expansion by in situ tethering of hydroxy azides to ketones: the Boyer reaction. Tetrahedron 53, 16241-16252 (1997). (Pubitemid 27492199)
39. Smith, B. T., Wendt, J. A. & Aube, J. First asymmetric total synthesis of (and)- sparteine. Org. Lett. 4, 2577-2579 (2002).
40. Meyer, A. M., Katz, C. E., Li, S-W., Vander Velde, D. & Aube, J. A tandem Prins/Schmidt reaction approach to marine alkaloids: formal and total syntheses of lepadiformines A and C. Org. Lett. 12, 1244-1247 (2010).
41. Fenster, E. et al. Three-component synthesis of 1,4-diazepin-5-ones and the construction of g-turn-like peptidomimetic libraries. J. Comb. Chem. 10, 230-234 (2008).
42. Trost, B. M. & Bogdanowicz, M. J. New synthetic reactions. X. Versatile cyclobutanone (spiroannelation) and g-butyrolactone (lactone annelation) synthesis. J. Am. Chem. Soc. 95, 5321-5334 (1973).
43. Li, X. & Danishefsky, S. J. Cyclobutenone as a highly reactive dienophile: expanding upon Diels-Alder paradigms. J. Am. Chem. Soc. 132, 11004-11005 (2010).
44. Xue, L., Stahura, F. & Bajorath, J. in Chemoinformatics Vol. 275 (ed. Jurgen Bajorath) Ch. 9, 279-289 (Humana, 2004).
45. Kopp, F., Stratton, C. F., Akella, L. B. & Tan, D. S. A diversity-oriented synthesis approach to macrocycles via oxidative ring expansion. Nature Chem. Biol. 8, 358-365 (2012).
46. Sauer, W. H. B. & Schwarz, M. K. Molecular shape diversity of combinatorial libraries: a prerequisite for broad bioactivity. J. Chem. Inf. Comput. Sci. 43, 987-1003 (2003).
47. Veber, D. F. et al. Molecular properties that influence the oral bioavailability of drug candidates. J. Med. Chem. 45, 2615-2623 (2002). (Pubitemid 34595232)
48. Bauer, R. A., Wurst, J. M. & Tan, D. S. Expanding the range of druggable targets with natural product-based libraries: an academic perspective. Curr. Opin. Chem. Biol. 14, 308-314 (2010).